Effect of Caraway Powder consumption on the Treatment of Type 2 Diabetes

The effect of Caraway powder consumption on glycemic indices, lipid profile and Serum levels of nesfatin-1 in overweight and obese patients with type 2 diabetes

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181207041876N1

Enrollment

Registered

2019-01-18

Start date

2019-04-09

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes. Type 2 diabetes mellitus without complications

Interventions

Intervention 1: The intervention group consumes 2 grams of Caraway powder capsules (one gram capsule after lunch and one gram capsule after a dinner) approved by the College of Pharmacy, Kerman Unive

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: given diabetes and having a fasting blood suger level of 126 to 250 mg / dL Consumption of oral glucose-lowering medicines Age range of 30 to 65 years Body mass index 25 to 40

Exclusion criteria

Exclusion criteria: given Chronic diseases (high blood pressure, heart, kidney, hypothyroidism, liver, systemic infection) Pregnancy and lactation Hypersensitivity to Caraway

Design outcomes

Primary

Measure	Time frame
Fasting Blood Suger. Timepoint: One day before intervention and one day after end of intervention. Method of measurement: Enzymatic method using kits.;Nesfatin-1. Timepoint: One day before intervention and one day after intervention. Method of measurement: Enzymatic method using ELISA kit.;Triglycerides. Timepoint: One day before intervention and one day after intervention. Method of measurement: Enzymatic method using kits.;Fasting Blood insulin. Timepoint: One day before intervention and one day after intervention. Method of measurement: Enzymatic method using ELISA kit.;Insulin resistance. Timepoint: One day before intervention and one day after intervention. Method of measurement: The product of fasting glucose concentration in fasting insulin concentration divided by constant number 22.5.;High density lipoprotein. Timepoint: One day before intervention and one day after intervention. Method of measurement: Enzymatic method using kits.;Low density lipoprotein. Timepoint: One day before intervention and one day after intervention. Method of measurement: Enzymatic method using kits.;Total cholesterol. Timepoint: One day before intervention and one day after intervention. Method of measurement: Enzymatic method using kits.	—

Measure

Time frame

Fasting Blood Suger. Timepoint: One day before intervention and one day after end of intervention. Method of measurement: Enzymatic method using kits.;Nesfatin-1. Timepoint: One day before intervention and one day after intervention. Method of measurement: Enzymatic method using ELISA kit.;Triglycerides. Timepoint: One day before intervention and one day after intervention. Method of measurement: Enzymatic method using kits.;Fasting Blood insulin. Timepoint: One day before intervention and one day after intervention. Method of measurement: Enzymatic method using ELISA kit.;Insulin resistance. Timepoint: One day before intervention and one day after intervention. Method of measurement: The product of fasting glucose concentration in fasting insulin concentration divided by constant number 22.5.;High density lipoprotein. Timepoint: One day before intervention and one day after intervention. Method of measurement: Enzymatic method using kits.;Low density lipoprotein. Timepoint: One day before intervention and one day after intervention. Method of measurement: Enzymatic method using kits.;Total cholesterol. Timepoint: One day before intervention and one day after intervention. Method of measurement: Enzymatic method using kits.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaber Jafari Maskouni

Zahedan University of Medical Sciences

saberjafarimaskouni@gmail.com+98 34 4335 0154

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 26, 2026